Honz Pharmaceutical Co., Ltd. announced that it expects to receive CNY 634.6114 million in funding
November 08, 2020
Share
Honz Pharmaceutical Co., Ltd. (SZSE:300086) announced a private placement of not more than 135,000,000 A shares for gross proceeds of CNY 634,611,400 on November 9, 2020. The maximum number of issued shares does not exceed 30% of total share capital before the issuance. The pricing base date of this transaction is the first day of the issue period, and the issue price is not less than 80% of the average price of the company's stocks 20 trading days before the first day of the issue period. The transaction included participation from not more than 35 special investors. The share will issue at par value of CNY 1. The transaction has been approved by 10th meeting of the 5th directorate of the company and are subject to the approval of the company's shareholders meeting, Shenzhen Stock Exchange and the China Securities Regulatory Commission. The shares issued are subject to a hold period of 6 months from the date of issuance. The transaction is valid for 12 months from the date of deliberation and approval by the company's shareholders meeting.
HONZ PHARMACEUTICAL CO., LTD., formerly HAINAN HONZ PHARMACEUTICAL CO., LTD., is principally engaged in the research, development, production and distribution of drugs for children. The Company provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The Company's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.